Amyotrophic Lateral Sclerosis (ALS)

Recent research in amyotrophic lateral sclerosis (ALS) includes findings involving the CRMP4, FUS and TDP43 genes.

Rare variant in the CRMP4 gene is associated with ALS

A study conducted in France and Sweden has identified an association between a rare variant in the gene for the collapsing response mediator protein 4 (CRMP4) protein and ALS.

Identification of the biological mechanisms that underlie amyotrophic lateral sclerosis (ALS) may provide scientists with important clues about the disease that may be used to identify biomarkers and potential biolo

A team of researchers in the U.S. and Australia has shed new light on sporadic amyotrophic lateral sclerosis (ALS), finding that some people with the disorder have gene mutations that may be associated with ALS and that do not exist in either of their parents — so-called de novo mutations.

Recently announced data from a phase 1 clinical trial of NSI-566 neural stem cells in people with amyotrophic lateral sclerosis (ALS) show that a subset of trial participants had better outcomes than the others.

The Muscular Dystrophy Association has designated the MDA clinic at Louisiana State University Health Sciences Center School of Medicine in New Orleans as an MDA/ALS center. This brings the total number of these specialized clinics to 44.

A phase 2 clinical trial to test the experimental drug GM604 in people with amyotrophic lateral sclerosis (ALS) has opened at two trial sites in the United States. Enrollment is expected to begin soon.

Melatonin, a naturally occurring hormone produced by the pineal gland, is best known for its role in regulating sleep.

An MDA-supported research team has identified a series of compounds that appear to work both alone and in combination to protect the muscle-controlling nerve cells (motor neurons) that are lost in amyotrophic lateral sclerosis (ALS).